In this multicentric real-world observational retrospective study, we evaluated the efficacy and safety of dupilumab for atopic dermatitis in children <6 years of age who underwent a minimum of 16 weeks of therapy. The analysis focused on EASI (Eczema Area and Severity Index), CDLQI (Children's Dermatology Life Quality Index), and Itch NRS (Numeric Rating Scale) changes from baseline to 4, 16, 24, 48, 72, and 96 weeks of follow-up (when available). Overall 24 children were included, with a mean age of 4.4 years. The baseline mean EASI among these patients was 26.7 (range 11.2-42.5). Since week 16 of therapy, all patients achieved and sustained at least 50% (EASI-50) atopic dermatitis improvement from baseline for the remainder of the follow-up period. At week 16, the mean EASI was 4.6 (0.8-13.1), EASI-75 reached 75% and EASI-90 38% of the patients. Within the initial 16 weeks of dupilumab treatment, 50% of patients experienced at least one adverse event, none of which were deemed severe. Conjunctivitis was among the most common adverse events (8.3%). In conclusion, dupilumab exhibited favorable tolerability, efficacy, and safety in children diagnosed with atopic dermatitis who were below the age of 6.

• MeSH
• Dermatitis, Atopic * drug therapy   MeSH
• Child MeSH
• Antibodies, Monoclonal, Humanized * adverse effects   therapeutic use   MeSH
• Infant MeSH
• Quality of Life MeSH
• Humans MeSH
• Child, Preschool MeSH
• Retrospective Studies MeSH
• Severity of Illness Index * MeSH
• Treatment Outcome MeSH
• Check Tag
• Child MeSH
• Infant MeSH
• Humans MeSH
• Male MeSH
• Child, Preschool MeSH
• Female MeSH
• Publication type
• Journal Article MeSH
• Multicenter Study MeSH
• Observational Study MeSH

• Keywords
• baricitinib,
• MeSH
• Alopecia Areata drug therapy   psychology   MeSH
• Dermatitis, Atopic * drug therapy   psychology   MeSH
• Cyclosporine administration & dosage   MeSH
• Adult MeSH
• Janus Kinase Inhibitors * administration & dosage   MeSH
• Humans MeSH
• Disease Progression MeSH
• Check Tag
• Adult MeSH
• Humans MeSH
• Male MeSH
• Publication type
• Case Reports MeSH

• MeSH
• Biological Therapy methods   MeSH
• Dermatology * trends   MeSH
• Venereology * trends   MeSH
• Publication type
• Interview MeSH

• MeSH
• Antibodies, Monoclonal, Humanized pharmacology   therapeutic use   MeSH
• Inflammatory Bowel Diseases etiology   MeSH
• Interleukin-17 antagonists & inhibitors   adverse effects   therapeutic use   MeSH
• Interleukin-23 antagonists & inhibitors   adverse effects   therapeutic use   MeSH
• Clinical Studies as Topic MeSH
• Humans MeSH
• Mycoses etiology   MeSH
• Arthritis, Psoriatic drug therapy   MeSH
• Psoriasis * drug therapy   MeSH
• Check Tag
• Humans MeSH

Upadacitinib je selektivní inhibitor JAK1, který je stále jednou z nejnovějších terapií atopické dermatitidy. V současné době již máme k dispozici téměř tříletá data o účinnosti a bezpečnosti dlouhodobé léčby atopického ekzému upadacitinibem a rovněž první soubory pacientů léčených upadacitinibem v reálné praxi. Všechny tyto výsledky potvrzují dobrou účinnost i bezpečnost upadacitinibu, který nevykazuje nové bezpečnostní signály či nárůst nežádoucích účinků v průběhu dlouhodobé terapie.

Upadacitinib is a selective JAK1 inhibitor that is still one of the newest therapies available for atopic dermatitis. Currently, we already have almost three-year data on the efficacy and safety of long-term treatment of atopic eczema with upadacitinib, as well as the first studies of patients from real practice. All these results confirm the good efficacy and safety of upadacitinib, which does not show any new safety signals or an increase in adverse effects during long-term therapy.

• Keywords
• upadacitinib,
• MeSH
• Dermatitis, Atopic * drug therapy   immunology   MeSH
• Biological Therapy MeSH
• Outcome Assessment, Health Care * MeSH
• Janus Kinase Inhibitors pharmacology   therapeutic use   MeSH
• Janus Kinase 1 antagonists & inhibitors   MeSH
• Clinical Trials as Topic MeSH
• Humans MeSH
• Meta-Analysis as Topic MeSH
• Check Tag
• Humans MeSH

x

x

• Keywords
• studie ADvocate 1, studie ADvocate 2, studie ADhere, studie ADore, lebrikizumab,
• MeSH
• Data Analysis MeSH
• Dermatitis, Atopic * diagnosis   drug therapy   MeSH
• Biological Therapy * classification   MeSH
• Interleukin Inhibitors * administration & dosage   pharmacology   adverse effects   therapeutic use   MeSH
• Injections, Subcutaneous methods   MeSH
• Clinical Trials as Topic MeSH
• Humans MeSH
• Treatment Outcome MeSH
• Check Tag
• Humans MeSH

• MeSH
• Biological Therapy MeSH
• Dermatology * trends   MeSH
• Interleukin Inhibitors pharmacology   therapeutic use   MeSH
• Skin Diseases drug therapy   MeSH
• Psoriasis * drug therapy   MeSH
• Publication type
• Interview MeSH

Risankizumab je monoklonální protilátka zacílená proti interleukinu-23, jednomu z nejvýznamnějších cytokinů uplatňujících se v patogenezi psoriázy. V randomizovaných klinických studiích byl prokázán vyšší účinek risankizumabu v porovnání s placebem i dalšími biologickými léčivy, jako jsou ustekinumab, adalimumab či secukinumab. Recentní klinická data zároveň potvrzují jeho vysokou účinnost z hlediska dosahování nově navržených léčebných cílů (absolutní skóre PASI ≤ 3, PASI ≤ 1, PASI = 0; skóre DLQI 0/1) a významný přínos i u pacientů s obtížně léčitelnými projevy psoriázy (psoriáza nehtů, kštice a palmoplantární psoriáza). Risankizumab se vyznačuje rovněž příznivým bezpečnostním profilem, a to i v dlouhodobém časovém horizontu, a přináší tak významné zlepšení kvality života nemocným s psoriázou.

Risankizumab is a monoclonal antibody targeting interleukin-23, one of the most important cytokines involved in the pathogenesis of psoriasis. In randomized clinical trials, risankizumab has been shown to be superior to placebo as well as other biologic agents such as ustekinumab, adalimumab or secukinumab. Recent clinical data also confirm its high efficacy in terms of achieving the newly proposed treatment goals (absolute PASI score ≤ 3, PASI ≤ 1, PASI = 0; DLQI score 0/1) as well as its significant benefit in patients with difficult-to-treat psoriasis manifestations (nail psoriasis, scalp psoriasis and palmoplantar psoriasis). Risankizumab is characterised by a favourable safety profile, even in the long term, and it thus brings considerable improvement in the quality of life of psoriasis patients.

• Keywords
• risankizumab,
• MeSH
• Biological Therapy methods   MeSH
• Humans MeSH
• Antibodies, Monoclonal administration & dosage   pharmacology   MeSH
• Psoriasis * drug therapy   MeSH
• Check Tag
• Humans MeSH
• Publication type
• Review MeSH